Proposal for a COUNCIL REGULATION (EC) providing for duty free treatment for specified pharmaceutical active ingredients bearing an "international nonproprietary name" (INN) from the World Health Organisation and specified products used for the manufacture of finished pharmaceuticals and withdrawing duty free treatment as pharmaceutical products from certain INNs whose predominate use is not pharmaceutical
Date: 1996-12-11
Institutions: European Commission
Subjects: World Health Organisation, chemical product, pharmaceutical product, product designation, tariff exemption, tariff nomenclature

i  COMMISSION  OF THE  EUROPEAN  COMMUNITIES 

Brussels,  11.12  1996 
COM(96)  563  final 

96/0268  (ACC) 

Proposal  for  a 

COUNCIL  REGULATION  (EC) 

Providing  for  duty free  treatment  for  specified  pharmaceutical  active  ingredients  bearing 
an  "international  nonproprietary  name"  (INN)  from  the  World  Health  Organisation  and 
specified  products used for the manufacture  of finished  pharmaceuticals  and withdrawing 
duty free treatment as pharmaceutical  products from certain INNs whose predominate  use 
is not pharmaceutical. 

(presented  by  the  Commission) 

EXPLANATORY  MEMORANDUM 

1.  Pursuant  to  the  conclusions  reached  in  Uruguay  Round  Record  of  Discussions 
(L/4740  of  25.3.1994)  on  duty  free  treatment  for  pharmaceutical  products,  the 
Commission  has participated in the first review of the product coverage to include, by 
consensus, additional products for duty free  treatment. 

2.  The  outcome  of  the  review  is  that  231  pharmaceutical  active  ingredients  bearing an 
"international  nonproprietary  name"  (INN)  from  the World  Health  Organisation  and 
234_products used for the manufacture  of finished  pharmaceuticals should be added to 
the  list  of  products  already  receiving  duty  free  treatment  and  also  that  the  list  of 
specified  prefixes  and suffixes  for  salts and esters of INNs should be expanded by 84 
names. 

3.  In  addition  it  was  concluded  that  the  situation  should  be  rectified  in  respect  of  25 
INNs  whose  use  was  predominantly  non-pharmaceutical  by  deleting  them  from  the 
list of INNs receiving duty free treatment. 

4.  The Commission proposes in line with other countries granting duty free treatment for 
these additional products as early as possible in  1997 that the duty free  treatment shall 
commence from  1.1.97. 

5.  For  these  reasons  the  Commission  proposes  that  the  Council  adopt  the  Regulation 

contained in the Annex to this communication. 

a. 

PROPOSAL FOR A COUNCIL REGULATION  (EC) 

Providing  for  duty  free  treatment  for  specified  pharmaceutical  active  ingredients  bearing 
an  "international  nonproprietary  name"  (INN)  from  the  World  Health  Organisation  and 
specified  products used for the manufacture  of finished  pharmaceuticals  and  withdrawing 
duty free treatment as pharmaceutical products from  certain INNs whose predominant use 
is not pharmaceutical 

THE COUNCIL OF THE EUROPEAN UNION 

Having  regard  to  the  Treaty  establishing  the  European  Community,  and  in  particular 
Article  113 thereof, 

Having regard to the proposal from the Commission, 

Whereas, in the course of the Uruguay Round negotiations the Community  and a number 
of countries discussed duty free treatment of pharmaceutical products; 

Whereas  the  participants  in  those  discussions  concluded  that  in  addition  to  products 
falling  in  the Harmonised  System  (HS)  chapter  30  and  HS  Headings  2936,  2937,  2939 
and  2941,  duty  free  treatment  should  be  given  to  designated  pharmaceutical  active 
ingredients bearing an "international  nonproprietary  name" (INN) from  the World  Health 
Organisation  as well  as specified  salts, esters  and hydrates  of  such  products,  and  also to 
designated products used for the production and manufacture  of finished  products; 

Whereas  the  results  of  the  discussions,  as  set  out  in  the  Record  of  Discussions1,  were 
incorporated  into  the  tariff  schedules  of  the  participants  annexed  to  the  Marrakesh 
Protocol to GATT 1994; 

Whereas  they  also  concluded  that  representatives  of  the  WTO  members  party  to  the 
Record  of discussions  would  meet under the auspices  of the Council  for  Trade  in  Goods 
of  the  WTO, normally  at  least  once  every  three  years  -  to  review  the  product  coverage 
with  a  view  to  including,  by  consensus,  additional  pharmaceutical  products  for  tariff 
elimination; 

Whereas  the first  such  review  has  taken  place  with  the  conclusion  that  additional  INNs 
and products used for production  and manufacture  of finished  pharmaceuticals  should be 
granted duty free treatment and that the list of specified  prefixes  and suffixes  for salts and 
esters of INNs should be expanded; 

Whereas  in the context  of  the  review  it  was concluded  that  it  was  appropriate  to  rectify 
the  situation  with  regard  to  certain  INNs  whose  use  was  predominantly  non-
pharmaceutical  and  which  had  been  inadvertently  included  among  those  INNs  already 
receiving duty free treatment. 

1 GATT Document  L/7430 

HAS ADOPTED THIS REGULATION: 

Article 1 

From  1 January  1997 the Community  shall  also  accord  duty  free  treatment  for  the INNs 
listed in Annex I as well as the salts, esters and hydrates of such products. 

Article 2 

From  1  January  1997  the  Community  shall  also  accord  duty  free  treatment  for  the 
products  used  in  the  production  and  manufacture  of  pharmaceutical  products  listed  in 
Annex II. 

Article 3 

From  1 January  1997  the  specified  prefixes  and  suffixes  of  INNs  eligible  for  duty  free 
treatment shall also include those listed in Annex III. 

Article 4 

From  1 January  1997 the products  listed  in Annex  IV together  with  the  salts, esters  and 
hydrates of such products shall no longer benefit from duty free  treatment. 

Article 5 

This  Regulation  shall  enter  into force  on the  day following  that  of  its publication  in  the 
Official  Journal of the European Communities. 

This  Regulation  shall  be  binding  in  its  entirety  and  directly  applicable  in  all  Member 
states. 

Done at Brussels, 

For the Council 

The President 

\ 

Additional INNs to receive duty free treatment 

Annex I 

Annex II 

Additional pharmaceutical intermediates, ie compounds used for the manufacture of 
finished pharmaceutical products, to receive duty free treatment. 

Annex III 

Additions to the list of prefixes and suffixes  which, in combination with the INNs, 
describe salts, esters or hydrates of INNs. 

INNs which shall no longer benefit from duty free treatment 

Annex IV 

FINANCIAL STATEMENT 

Section 1. 

Financial  Implications 

1.  Proposal  for  a  Council  Regulation  providing  duty  free 

treatment  for  465 
pharmaceutical products and withdrawing duty free treatment from  25 products whose 
predominant use is not pharmaceutical. 

2.  Budget heading: 

(loss of revenue: not known) 

3.  Legal basis: 

Article  113 

4.  Description 

The  proposal  regulation  is  a consequence  of  the  agreement  reached  in  the  Uruguay 
Round  to undertake  a periodic  review  of the  agreement  with  a view  to including, by 
consensus, additional products for duty free treatment. 

5.  Type of revenue:  Loss of revenue for duties paid on third country imports. 

6.  Change in level of revenue: 

The  withdrawal  of  duty  free  treatment  from  products  whose  use  was  predominantly 
non-pharmaceutical  with  subsequent  revenue  gains  will  offset  a  large  proportion  of 
the  revenue  loss  for  duty  free  treatment  being  granted  to  other  products.  No  figures 
are  available  for  the  amounts  involved  but  with  this  element  taken  into  account  the 
duty loss is likely to be less than 2 MECU. 

Annex I 

Additional INNs to receive duty free  treatment 

•\ 

CN code 

CAS KW 

Nam» 

2844 40 30 

2846 90 00 

2914 40 90 
2916 39 00 
2918 30 00 

2918 90 90 
2921 49 90 
2922 49 70 
2923  90 00 
2924 10 00 

2924 29 90 

2925 19 80 
2925 20 00 
2926 90 80 

2928 00 90 
2930 90 16 
2930 90 70 

2931 00 50 
2931 00 80 

2932 99 70 
2932 99 90 

2933 29 90 

2933 39 95 

2933 40 10 

113716-48-6 
142481-95-6 
131069-91-5 
135326-11-3 
138721-73-0 
20098-14-0 
71109-09-6 
22161-81-5 
112665-43-7 
139403-31-9 
136236-51-6 
6582-31-6 
1794-75-8 
1675-66-7 
62304-98-7 
132787-19-0 
129009-83-2 
147362-57-0 
94497-51-5 
144849-63-8 
137159-92-3 
137109-71-8 
147076-36-6 
141579-54-6 
87573-01-1 
90357-06-5 
112573-72-5 
107023-41-6 
81110-73-8 
132236-18-1 
114084-78-5 
124351-85-5 
63132-39-8 
105674-77-9 
123407-36-3 
132017-01-7 
110816-79-0 
149494-37-1 
151581-24-7 
113806-05-6 
139110-80-8 
158682-68-9 
116684-92-5 
89371-44-8 
138402-11-6 
118072-93-8 
119257-34-0 
118248-91-2 
155415-08-0 
121750-57-0 
144412-49-7 
155319-91-8 
150443-71-3 
29876-14-0 
144035-83-6 
137795-35-8 
147025-53-4 
149488-17-5 
127294-70-6 
143383-65-7 
143224-34-4 

iolopride  (123 I) 
technetium  (99m Tc)  furifosmin 
gadoversetamide 
gadoxetic acid 
sprodiamide 
idramantone 
vedaprofen 
dexketoprofen 
seratrodast 
pimilprost 
rasagiline 
dapabutan 
laurcetium bromide 
adelmidrol 
thymalfasin 
tradecamide 
versetamide 
loviride 
tamibarotene 
bisnafide 
aptiganel 
balazipone 
laflunimus 
fenleuton 
salnacedin 
bicalutamide 
dexecadotril 
pobilukast 
racecadotril 
zifrosilone 
ibandronic acid 
incadronic acid 
olpadronic acid 
lanproston 
arteflene 
bervastatin 
cromoglicate lisetil 
ebalzotan 
iralukast 
olopatadine 
zanamivir 
elisartan 
galdansetron 
imidaprilat 
irbesartan 
zoledronic acid 
besipirdine 
fodipir 
inogatran 
itameline 
lamifiban 
mangafodipir 
nicanartine 
nicotredole 
piclamilast 
spiroglumide 
talsaclidine 
trovirdine 
balofloxacin 
premafloxacin 
telinavir 

2933 40 90 
2933 40 90 

2933 59 70 

2933 79 00 

2933 90 95 

2934 10 00 

2934 20 90 

2934 90 60 

2934 90 70 

2934 90 80 
2934 90 98 

96946-42-8 
158966-92-8 
136668-42-3 
127266-56-2 
106941-25-7 
113852-37-2 
150756-35-7 
119687-33-1 
127759-89-1 
140945-32-0 
134208-17-6 
96604-21-6 
148504-51-2 
115762-17-9 
118420-47-6 
137234-62-9 
151319-34-5 
148396-36-5 
74436-00-3 
143943-73-1 
106730-54-5 
135548-15-1 
145733-36-4 
143343-83-3 
137882-98-5 
114607-46-4 
120511-73-1 
134523-00-5 
128270-60-0 
139481-59-7 
54278-85-2 
105806-65-3 
62568-57-4 
120081-14-3 
142880-36-2 
62732-44-9 
116287-14-0 
112809-51-5 
116644-53-2 
136122-46-8 
144702-17-0 
132036-88-5 
106308-44-5 
144701-48-4 
147059-72-1 
149079-51-6 
128312-51-6 
51287-57-1 
101001-34-7 
136433-51-7 
138742-43-5 
144665-07-6 
150915-41-6 
146939-27-7 
130370-60-4 
133040-01-4 
135202-79-8 
114686-12-3 
132418-36-1 
132418-35-0 
125533-88-2 
127045-41-4 
118292-40-3 
151356-08-0 

cisatracurium besilate 
montelukast 
quiflapon 
adatanserin 
adefovir 
cidofovir 
efletirizine 
iganidipine 
lobucavir 
mapinastine 
mazapertine 
ocinaplon 
ripisartan 
ruzadolane 
tagorizine 
voriconazole 
zaleplon 
fradafiban 
geclosporin 
lirequinil 
olprinone 
oxeclosporin 
tasosartan 
toborinone 
abitesartan 
acitazanolast 
anastrozole 
atorvastatin 
bivalirudin 
candesartan 
candocuronium iodide 
efegatran 
emideltide 
goralatide 
ilomastat 
ipidacrine 
lanperisone 
letrozole 
mibefradil 
mipitroban 
pomisartan 
ramosetron 
rufinamide 
telmisartan 
trovafloxacin 
cartasteine 
cinalukast 
denotivir 
pamicogrel 
tazofelone 
zankiren 
lubeluzole 
perospirone 
ziprasidone 
batimastat 
eprosartan 
ilonidap 
imitrodast 
rocepafant 
setipafant 
mofarotene 
pazufloxacin 
tazarotene 
afovirsen 

138298-79-0 
152317-89-0 
153420-96-3 
143393-27-5 
149908-53-2 
150490-85-0 
154361-50-9 
133099-04-4 
137500-42-6 
114030-44-3 
115464-77-2 
141790-23-0 
122254-45-9 
143443-90-7 
82857-82-7 
104454-71-9 
118288-08-7 
138068-37-8 
78994-23-7 
116476-16-5 
148152-63-0 
84558-93-0 
147432-77-7 
139225-22-2 
103255-66-9 
123447-62-1 
131986-45-3 
145781-32-4 
147536-97-8 
136817-59-9 
119905-05-4 
112966-96-8 
125279-79-0 
139133-26-9 
154397-77-0 
139133-27-0 
116649-85-5 
133276-80-9 
146623-69-0 
149556-49-0 
144494-65-5 
139308-65-9 
107753-78-6 
131875-08-6 
9002-68-0 
152923-57-4 
103466-73-5 
144459-70-1 
124478-60-0 
140703-51-1 
133107-64-9 
144743-92-0 
151581-23-6 
132210-43-6 
100324-81-0 
98833-92-2 
135905-89-4 
117086-68-7 
25775-90-0 
133692-55-4 
127785-64-2 
116853-25-9 
122841-10-5 
156131-91-8 

alnespirone 
alniditan 
atibeprone 
azalanstat 
azimilide 
berupipam 
capecitabine 
darifenacin 
darsidomine 
dexpemedolac 
elopiprazole 
fozivudine tidoxil 
glenvastatin 
ifetroban 
ilepcimide 
ipenoxazone 
lafutidine 
lepirudin 
levormeloxifene 
levosemotiadil 
napitane 
netivudine 
ontazolast 
panâmesine 
pazinaclone 
prulifloxacin 
xanomeline 
zolasartan 
bosentan 
delavirdine 
delequamine 
domitroban 
ersentilide 
lexipafant 
napsagatran 
nupafant 
ramatroban 
samixogrel 
saprisartan 
susalimod 
tirofiban 
tolafentrine 
zafirlukast 
lexacalcitol 
follitropin alfa 
lutropin alfa 
icometasone enbutate 
rofleponide 
aglepristone 
examorelin 
insulin lispro 
teverelix 
apaxifylline 
cipamfylline 
lisofylline 
stacofylline 
mirisetron 
ricasetron 
zucapsaicin 
seprilose 
basifungin 
cefluprenam 
cefoselis 
dimadectin 

fa 

2935 00 90 

2936 29 90 
2937 10 10 

2937 22 00 
2937 29 90 
2937 99 00 

2939 50 90 

2939 90 90 

2940 00 90 
2941 90 00 
2941 90 00 

123997-26-2 
149951-16-6 
108852-90-0 
159445-62-2 
156769-21-0 
120993-53-5 
143653-53-6 
156227-98-4 
151763-64-3 
152923-56-3 
145832-33-3 
142864-19-5 
152981-31-2 
150631-27-9 
159445-64-4 
147191-91-1 
153101-26-9 
148189-70-2 
143090-92-0 
143631-61-2 
148637-05-2 
154725-65-2 
148363-16-0 
102786-52-7 
156679-34-4 
124146-64-1 
0-00-0 
148641-02-5 
139076-62-3 
0-00-0 
0-00-0 
143831-71-4 
154248-97-2 
149394-67-2 
156616-23-8 
159445-63-3 
155773-57-2 
95522-45-5 
31512-74-0 
39464-87-4 
0-00-0 
0-00-0 

eprinomectin 
lenapenem 
nemorubicin 
orientiparcin 
sanfetrinem 
desirudin 
abciximab 
afelimomab 
capromab 
dacliximab 
detumomab 
enlimomab 
inolimomab 
nacolomab tafenatox 
odulimomab 
priliximab 
regavirumab 
votumumab 
anakinra 
atexakin alfa 
cilmostim 
epoetin epsilon 
epoetin omega 
eptacog alfa  (activated) 
lenercept 
mobenakin 
moroctocog alfa 
muplestim 
octocog alfa 
plusonermin 
fuladectin 
dornase alfa 
imiglucerase 
ledismase 
monteplase 
nateplase 
pegorgotein 
colestilan 
polixetonium chloride 
betasizofiran 
certoparin sodium 
minolteparin sodium 

3001 90 99 
3002 10 91 

3002 10 95 

3003 39 00 
3003 90 90 
3507 90 90 

3911 90 19 

3913 90 80 

11 

Annex II 

Additional  pharmaceutical  intermediates, ie compounds used for the manufacture  of 
finished pharmaceutical products, to receive duty free treatment. 

43. 

est coda 

CAS R» 

game 

^^ 

2843 30 00 
2903 69 90 

12192-57-3  (alpha-D-glucopyranosylthioJgold 
42074-68-0  l-chloro-2-(chlorodiphenylmathyl)benzene 
76283-09-5  alpha,4-dibromo-2-filuorotoluene 

2906 29 90  104265-58-9  2-[(is,2R)-6-fluoro-2-hydroxy-1-isoprdpyl-

l,2,3,4-tetrahydro-2-naphthyllethyl p-
toluenasulfonate 

2907 29 90 
2909 50 90 
2914 40 90 
2914 50 00 

700-13-0  2, 3,5-triraethylhydjroquinane 

63659-16-5  4-  [2-(cyclopropylmethoxy)ethyl]phenol 
80-75-1  ll-alpha-hydroxypregn-4-9ne-3,20-d±ane 

2107-69-9  5,6-diraethoxyindan-l-one 

2914 70 90 

2915 39 90 
2915 90 20 
291a 39 00 

2917 19 90 

2917 39 80 
2918 13 00 
2918 17 00 
2918.19 80 

24916-90-3  9-beta,11-beta-epoxy-l7,2l-dihydroxy-lS-alpha-
methylpregna-l,4-diene-3,20-dione 
83881-08-7  21-chloro-9-beta",11-beta-epoxy-17-hydroxy-16-

alpha-methylpregna-1,4-diene-3,20-dione 

979-02-2  2Q~oxopregna-5,16-dien-3-beta-yl acetate 
638-41-5  pexityl chloroformate  -. 

-, 

49708-81-8  trans-4-(p-ahlorophenyl)^yClohexanecarboxylic 

acid 

48059-97-8  (B) -oct-4-ei»r-l, 8-dloic "acid 
71170-82-6  triethyl 3-bramopropane-l,1,1-tricarboxylate 
27932-00-9  indan-5-yl hydrogen phenylmalonate 

2743-38-6  dibenzoyl-L-tartaric acid 
4358-88-7  ethyl DL-mandel'at* 

563.88-04-6  {(lit, 3R, 5S) ~3 , 5-dlhydroxy-2- [ (E) - (3S) -3-

hydroxyoct-l-enyl]cyclopentyl}ac«tic acid 

2918 29 90  167678-46-8  3-chloroformyl-o-tolyl acetate 
2918 30-00 

56105-81-8  (R) -2-(3-benzaylphenyl)propionic acid 
22161-86-0  • {RS)~2-{3-benzoylphenyl)propionic acid 
78834-75-0  ethyl 7-chloro-2-cocoheptanoate 

1944-S3-4  3- [ (3aS,4S,7aS)-7a-methyl-l,S-dioxoactahydro-

lH-inden-4-yl]propionic acid 

2918 90 90 

39562-17-9  methyl 2-(3-nitrobenzylidene)-3-oxobutyrate 
26159-31-9  (RS)-2-(6-methoxy-2-naphchyl)propionic, acid 

105560-93-8  methyl  (2R,3S)-2,3-epoxy-3-(4-

methoxyphenyl)propionate 

40098-26-8  methyl 7-[(3RS)-3-hydrpxy-S-oxocyclopent-l-

enyl]heptanoate 

2921 19 so 
2921 59 90 
2922 19 00  126456-43-7  (IS, 2R)-l-aminoindan-2-ol 

4261-68-1  (2-chloroethyl)diisopropylamine hydrochloride 
122-75-8  N,N'-dibenzylethylenediammonium di(acetate) 

68047-07-4  4'-[2-(dimethylamino)ethoxy]-2-
phenylbutyrophenone 

2922 30 00 

784-38-3  2~araino-5-chloro-2'-fluorob«nzophenone 

156732-13-7 (S)-5-amino-2-(dibenzylamino)-l,6~diphenylhex-

2922 49 70 

37441-29-5  5-amino-2,4,6-triiodoisophthaloyl dichloride 
42854-62-6  ben2yl L-alaninate--p-toluenesulfonic acid 

4~en73-one 

39878-87-0  (-)-alpha- (chloroformyl)benzylammonium 

(1:1) 

chloride 

54527-73-0  2-(N-methylbenzylamino)ethyl 3 -aminobut-2 -

enoate 

81677-60-3  methyl  (4-nitrophenyl)-L-alaninate 

949-99-5  3-(4-nitrophenyl)-L-alanine 
2924 10 00  153758-31-7  (2S)-2-aminb-3-hydroxy-N-pentylpropionamide--
oxalic acid (1:1) 

e 

ANNEX II 

CM code 

CAS RM 

Name 

13 8531-07-4  L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-

lyayl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-
lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-
lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-
lysine 

2924 29 90 
2924 29 90 

4018B-45-2  3'-aoetyl-4'-hydroxybutyranilide 
1149-26-4  N-(banzyloxycarbonyl)-L-valine 

116661-86-0  (2S,3S)-3-(tert-butoxycarbonylamino)-2-

bydroxy-4-pheiiylbutyric acid 
144163-85-9  tert-butyl  [(is,3S,4S)-4-amiao-l-benzyl-3-

hydroxy-5-phenylpentylJcarbamate 
149451-80-9  tert-butyl  [(IS,2S)-l-benzyl-2,3-

dihydroxypropyl]carbamate 
98737-29-2  tert-butyl  {IS)-alpha-[(S)-

oxiranyl]phenethyl}carbamate 

0-00-0  2-chloro-N-[2-(2-chlorob9nzoyl)-4-

nitrophenyl]acetamide 

125971-96-2  2- [alpha-(4-fluorobenzoyl)benzyl]-4-methyl-3-

oxovaleranilide 

32981-8S-4  methyl  (2R,3S)-3-benzamido-2-hydroxy-3-

phenylpropionate 

292.5 19 80  151860-15-0  meeo-N-benzyl-3-nitrocyclopropane-1,2-
dicarboximide 

97338-03-9  «thyl  (S)-3-(4-aminophenyl)-2-

phthalimidopropionate hydrochloride 

94213-26-0  ethyl  (S)-3-{4-[bis(2-

chloroethyl)amino]phenyl} -2-
phthalimidopropionate hydrochloride 

2926 90 80 

58311-73-2  (Z)-(2-cyanovinyl)trimethylammonium p-

toluenesulfonate 

133481-10-4  ethyl  (1-cyanocyclohexyl)acetate 
123632-23-5  4-(2,2,3,3 -tetrafluoropropoxy)cinnamon!trile 

2328 00 90 

94213-23-7  (Z)-[cyano(2,3-

2930 90 16  159453-24-4  N-(benzyloxycarbanyl)-S-phenyl-L-cysteine 
2930 90 70  159878-02-1  benzyl  (1R,2S)-3-chloro-2-hydroxy-l-

dichlorophenyl)methylene]carbazamidine 

(phenylthiomethyl)propylcarbamate 
136511-43-8  ethyl N-{2-[(acetylthio)methyl]-3-(o-tolyl)-1-

oxopropyl}-L-methionate 

2932 19 00 
2932 29 80 

97148-39-5  ammonium  (Z)-2-methoxyimino-2-(2-furyl)acetate 

517-23-7  alpha-acetyl-gamma-butyrolactone 

6559-91-7  4'-demethylepipodophyllotoxin 

3 9521-49-8  (3aR,4bS,4R,4aS,5aS)-4-(5,5-dimethyl-1,3-

2932 99 50 
2932 99 70 

dioxolan-2-
yl)hexahydrocyclopropa[3,4]cyclopenta[1,2-
b]furan-2(3H)-one 

39746-Q1-5  (3aR, 4R, 5R, 6aS) -4-formyl-2-oxohaxahydro-2H-
cyclopenta[b]furan-5-yl benzoate 
976-70-5  3-oxopregn-4-ene-21,17-alpha-carbolactone 

32981-86-5  ia-deacetylbaccatin III 

7512-17-6  2-acetamido-2-deoxy-beta-D-glucopyranose 

79944-37-9  trans-6-amino-2.2-dimethyl-1,3-dioxepan-5-ol 

125971-94-0  tert-butyl  [(4R,6R)-6-(cyanomethyl)-2,2-

dimethyl-i,3-dioxolan-4-yl]acetate 

467-55-0  3-beta-hydroxy-5 -alpha-epiro3tan-12-one 
533-31-3  3,4-(methylenedioxy)phenol 

4t 

CM code 

CAS RM 

Nana 

2933 11 90 

6150-97-6  magnesium bis[(2,3-dihydro-l, 5-dimethyl-3-oxo-

ANNEX II 

2-phenyl-IH-pyrazol-4 -
yl)methylamino]methanesulfonate 
27511-79-1  3-aminopyrazole-4-carbaxamide hemisulfate 

2933 19 90 
2933 29 90 
2933 39 95  142057-79-2  (RS)-2-[(l-benzyl-4-piperidyl)methyl]-5,6-

4897-25-0  5~chloro-l-methyl-4-nitroimidazale 

120014-07-5  2-[(l-benzyl-4-piperidyl)methylene]-5,6-

dimethoxyindan-l-one 

dimethoxyindan-1-one 

6 935-27-9  benzyl(2-pyridyl)amine 

2933 39 95 

87848-95-1  6-bromo-2-pyridyl p-tolyl ketone 
32998-95-1  N-(tert-butyl)-3-methylpyridina-2-carboxamide 
84449-80-9  1-[2-(4-carboxyphenoxy)ethyl]piperidinium 

chloride 

83949-32-0  4-carboxy-4-phenylpiperidinium p-

coluenesulfonate 

38092-89-6  8-chloro-6,ll-dihydro-11-(l-methyl-4-

piperidylidene)-SH-benzo[5,6]cyclohepta[l,2-
b]pyridine 

31255-57-9  3-[2-(3-chlorophenyl)ethyl]pyridine-2-

carbonitrile 

107256-31-5  3-[2-(3-chlorophenyl)ethyl]-2-pyridyl 1-
methyl-4-piperidyl ketone hydrochloride 

6298-19-7  2-chloro-3-pyridylamine 
5424-11-3  2,2-diphenyl-4-piperidinovaleronitrile 

108555-2S-5  1-[2-(4-methoxyphenyl)ethyl]-4-piperidylamine 

dihydrochloride 
4046-24-6  5-(l-methyl-4-piperidyl)-5H-

139886-0^-7  1-methyl-l,2,5,6-t«trahydropyridine-3-' 

dibenzo[a,d]cyclohepten-5-ol hydrochloride 

70708-28-0  1-(2-pyridyl)-3-(pyrrolidin-1-yl)-1-(p-

carbaldehyde  (E)-O-methyloxime hydrochloride 

tolyl)propan-l-ol 

1619-34-7  quinuclidin-3-ol 

2933 40 10  1059S6-96-5  7-[3-{tert-butoxycarbonylamino)pyrrolidin-1-

yl]-8-chloro-l-cyclopropyl-6-fluoro-4-oxo-l,4-
dihydroguinoline-3-carboxylic acid 

86393-33-1  7-chloro-1-cyclopropy1-6-f1uoro-4 -oxo-1,4-

dihydroquinoline-3-carboxylic acid 

H2811-72-0  l-cyclopropyl-6,7-difluoro-B-methoxy-4-oxo-

1,4-dihydroquinoline-3-carboxylic acid 

98349-25-8  ethyl 1-cyclopropyl-6,7-difluoro-4-oxo-l,4-
dihydroquinoline- 3 -carboxylate 

2933 40 90  159878-04-3  benzyl  (IS,2B)-3- [ (3S,4aS,8aS)-3-tert-
butylcarbamoylperhydro-2-isoguinolyl]-2-
hydroxy-1-(phenylthiomethyl)propylcarbamate 

15 9989-64-7  (3S,4aS,8aS)-N-(tert-butyl)-2-[(2S,3S}-2-

hydroxy-3- (3-hydraxy-2~methylbe.nzamido) -4-
(phenylthio)butyl]perhydroisoquinaline-3-
carboxarnide 

15 998 9-65-8  (3S,4aS,8aS)-N-(tert-butyl)-2-[(2S,3S)-2-
hydroxy-3-(3-hydroxy-2-methylbenzamido)-4-
(phenylthio)butyl]perhydroisoquinoline-3-
carboxamide--methane8Ulfonic acid  (1:1) 

120578-03-2  3-'[ (E) - 2 - (7 -chloro-2-

quinolyl)vinyl]benzaldehyde 

15 

ANNEX II 

CM code 

CAS RM 

H*»« 

1087-69-0  (9S,13S,14S)-3-methoxymorphinan hydrochloride 
64228-78-0  pent ante thyl ene bis{3-[i-(3,4-dimethoxybenzyl)-
6,7-dimathoxy-i,2,3,4-tetrahydro-2-
isoquinolyl]propionate}--oxalic acid  (1:2) 

2933 59 70 

75128-73-3  2-[(2-acetamido-6-0x0-6,9-dihydro-lH-purin-9-

yDmethoxy] ethyl acetate 

3056-33-5  N- (9-acetyl-6-oxo-6,9-dihydro-lH-purin-2-

10310-21-1  2-amino-6-chloropurine 

yl)acetamide 

124832-31-1  2-[(2-amino-6-oxo-l,6-dihydro-9H-purin-9-
yl)methoxy]ethyl N-(benzyloxycarboayl)-L-
valinate 

150378-17-9  (2R,4S)-2-benzyl-5-[2-(tert-butylcarbamoyl)-4-
(3-pyridylmethyl)piperaz in-1-yl]- 4 -hydroxy-N-
[ (1S.2R)-2-hydroxyindan-l-yl]valeramida 

2933 59 70  157810-81-6  (2R,4S)-2-benzyl-5-[2-(tert-butylcarbamoyl)-4-

(3-pyridylmethyl)piperazin-l-yl]-4-hydroxy-N-
[(IS,2R)-2-hydroxyindan-1-yl]valeramide 
sulfate 

150323-35-6  (3S)-1-(tert-butoxycarbonyl)-3-(tert-

butyl carbamoyl)pipera z ine 

41202-32-8  <l-(2-chlorophenyl)piperazine  hydrochloride 
13078-15-4  1-(3-chlorophenyl)piperazine hydrochloride 

71-30-7  cytoaine 

149062-75-9  1,3-dlchlorO-6,7,8,9,10, 12-

hexahydroazepino[2,l-b]quinazoline 
hydrochloride 

,41202-77-1  1-(2, 3-dichlorophenyl)piperazine hydrochloride 
56177-80-1  2-ethoxy-5-fluorapyrimidin-4(1H)-one 
112733-45-6  ethyl  (7-chloro-2,4-dioxo-l, 2 , 3 , 4-

59703-00-3  4-ethyl-2,3-dioxopiperazine-l-carbonyl 

tetrahydroquinazolin-1-yl)acetate 

chloride 

64090-19-3  1-(4-fluorophenyl)piperazine dihydrochloride 
147539-21-7  i3opropyl[2-(piperazin-1-yl)-3-pyridyl]amine 

35386-24-4  1-(2-methoxyphenyl)piperazine 

5464-78-8  1-(2-methoxyphenyl)piperazine hydrochloride 

145012-50-6  (7RS,9aRS)-perhydropyrido[l,2-a]pyrazin-7-

ylmethanol 

2210-93-7  1-phenylpiperaziniura chloride 

111641-17-9  4-(piperazin-1-yl)-2,6-bia(pyrrolidin-I-

yl)pyrimxdine 

68-94-0  purin-6(1H)-one 

2933 69 80 

70849-60-4  1-(o-tolyl)piperazine hydrochloride 
58909-39-0  tetrahydro-2-methyl-3-thioxo-l,2,4-criazine-

2933 79 00  135297-22-2  (3S,4R)-3-[(R)-1-(tert-

5.6-dione 

butyldimethylsilyloxy)ethyl]-4-[(lR,3S)-3-
methoxy-2-oxocyclohexyl]azetidin-2-one 

141646-08-4  l-{[(cyclohexyloxy)carbonyl]oxy}ethyl l-(l-
hydroxyethyl)- 5-methoxy-2-oxo-
1,2,5,6,7,8,8a,8b-octahydroazeto[2,1-
a]isoindale-4-carboxylate 

132127-34-5  (3R,4S)-3-hydroxy-4-phenylazetidin-2-one 

75363-99-4  p-nitrobenzyl  (2R.5R,6S)-6-[(R)-l-

hydroxyethyl]-3,7-dioxo-l-

ANNEX II 

CM code 

CAS RM 

141316-45-2  potassium l-(1-hydroxyethyl)-5-raethoxy-2-oxo-

azabicyclo[3 .2 . o] hop tane-2-car boxy late 

1,2,5,6,7,8,8a,8b-octahydroazeto[2,1-
a]isoindole-4-carboxylate 

2933 90 60 

59467-64-0  [7-chloro-5-(2-fluorophenyl)-2,3-dihydro-lH-

59469-29-3  [7-chloro-5-(2-fluorophenyl)-2,3-dihydro-lH-

1,4-benzodiazepin-2-yl]methylamine 

l,4-benzodiazepin-2-ylmethyl]ammonium 
bis(maleate) 

59467-69-5  8-chloro-6-(2-fluorophenyl)-l-methyl-3a,4-

dihydro-3H-imidazo[l', 5-a] [1, 4] benzodiazepine 

5946 9-63-5  7-chloro-5-(2-fluorophenyl)-3-methyl-2-

(nitromethylene)-2,3-dihydro-lH-l,4-
benzodiazepine 4-oxide 

59467-63-9  7-chloro-5-(2-fluorophenyl)-2-

(nitromethylene)-2,3-dihydro-lH-l, 4-
benzodiazapine 

2933 90 95  130404-91-0  N-[(R)-2-({(R)-2-[(2-

adamantyloxycarbonyl)amino]-3-(lH-indol-3-yl)-
2-methyl-1-oxopropyl}amino) -1 -
phenylethyl]succinamic acid--i-deoxy-l-
methylamino-D-glucitol (1:1) 
122536-48-5  3-[(S)-3-(L-alanylamino)pyrrolidin-i-yl]-i-
cyclopropyl-6-fluoro-4-oxo-l, 4-dihydro-l,8-
naphthyridine-3-carboxylic acid hydrochloride 

122536-91-8  7-{(S)-3-[(S)-2-(tert-butoxycarbonylamino)-l-

oxopropylamino]pyrrolidin-1-yl}-l-cyclopropyl-
6-fluoro-4-oxo-l,4-dihydro-l,8-naphthyridine-
3-carboxylic acid 

134575-17-0  tert-butyl meso-3-azabicyclo[3.1.0]hex-6-

122536-66-7  tert-butyl  { (S) -l-methyl-2-oxo-2- [ (S) -1 

ylcarbamate 

pyrrolidin-3-ylamino]ethyl}carbamate 

140629-77-2  tert-butyl  [(RS)-pyrrolidin-3-yl]carbamate 
100361-18-0  7-chloro-l-cyclopropyl-6-fluoro-4-oxo-l,4-

38150-27-5  S-chloro-2-[3-(hydroxymethyl)-5-methyl-4H-

dihydro-1,8-naphthyridine-3-carhoxylic acid 

1,2,4-triazol-4-yl]benzophenone 

36916-19-5  5-chloro-2- (3r-methyl-4H-l, 2 ,4-triazol-4-

yl )benzophenone 

54196-62-2  2' , 5-dichloro-2- [3- (hydroxymethyl) -5-mathyl-
4H-1,2,4-triazol-4-yl]benzophenone 

54196-61-1  2',5-dichloro-2-(3-methyl-4H-1,2,4-triazol-4-

141113-28-2  (E)-(+)-2-(2,4-difluorophenyl)-l-{3-[4-

yl)benzophenone 

(2,2,3,3-tecrafluoropropoxy)styryl]-1H-1,2,4-
triazol-i~yl}-3-(1H-1,2,4-triazol-l-yl)propan • 
2-ol 

141113-41-9  (R)-2-(2,4-difluorophenyl)-3-(1H-1, 2,4-

triazol-l-yl)propane-l,2-diol 

144034-80-0  dimethyl{2-[5-(1H-1,2,4-triazol-1-

122665-86-5  ethyl  [3-(cyanomechyl)-4-oxo-3, 4-

ylmethyl)indol-3-yl]ethyl)amine 

dihydrophthalazin-l-yl]acetate 

41340-36-7  2-(7-ethyl-iH-indol-3-yl)'ethanol 
95885-13-5  5-ethyl-4- (2-phenoxyethyl)-4H-1, 2 . 4»triazol-

^ 

ANNEX II 

CM coda 

CAS RN 

Name 

3 (2H) -one 

96107-94-7  ethyl  1H-tetrazole-5-carboxylate,  sodium  salt 
96034-57-0  trans-4-hydroxy-i-(4-nitrobenzyloxycarbonyl)-

L-proline 

160194-26-3  2-iodo-4-(1H-1,2.4-triazol-l-ylmethyl)aniline 

66635-71-0  isopropyl  2,3-dihydro-lH-pyrrolizine-l-

carboxylate 

4928-88-5  methyl  1H-1,2,4-triazole-3-carboxylate 

0-00-0  1,4,7,10-tetraazacyclododecane-i,4,7-triacetic 

acid  sulfate 

112193-77-8  1,4,7,10-tetraazoniacyclododecane bis(sulfate) 

—• 

—; 

3641-08-5  lH-l,2,4-triazole-3-carboxaroide 
4928-87-4  1H-1,2.4-triazole-3-carboxylic acid 
6969-71-7  l,2,4-triazolo[4,3-a]pyridin-3(2H)-one 

2934  10  00  171485-87-3  2-[4-(2-amino-4-oxo-4,5-dihydrothiazol-5-

ylmethyl)phénoxymethyl]-2,5,7,8-
tetramethylchroman-6-yl  acetate 

65872-41-5  (Z)-2-(2-aminothiazol-4-yl)-2-

methoxyiminoacetic  acid 

64486-18-6  (2)-2-[2-(chloroacetamido)thiazol-4-yl]-2-

76823-93-3  1-{4-[(2-cyanoethyl)thiomethyl]thiazol-2-

(mechoxyimino)acetic acid 

yl}guanidine 

2934  10  00  139340-56-0  (S-[(Z)-3,S-di(tert-butyl)-4-

hydroxybenzylidene]-4-oxo-4,5-dihydrothiazol-
2-yl}ammonium methanesulfonate 

64485-88-7  ethyl  (Z)-2-(2-aminothiazol-4-yl)-2 -

66339-00-2  ethyl  2-(hydroxyimino)-2-[2-

(methoxyimino)acetate 

(tritylamino)thiazol-4-yl]acetate 
hydrochloride 

88046-01-9  2-guanidinothiazol-4-ylmethyl 

carbamimidothioate  dihydrochloride 

154212-61-0  N-[2-isopropylthiazol-4-

ylmethyl(methyl)carbamoyl]-L-valine 

66215-71-2  (Z)-2-methoxyimino-2-[2-(tritylamino)thiazol-

154212-59-6  4-nitrophenyl  thiazol-5-ylmethyi  carbonate 

4-yl]acetic acid 

hydrochloride 

38585-74-9  thiazol-5-ylmethanol 

155213-67-5  thiazol-5-ylmethyl  (IS,2S,4S)-l-benzyl-2-

hydroxy-4-{(2S)-2-[3-(2-iaopropylthia2ol-4-
ylmethyl) -3-methylureido] -3-methylbuty*;avnido} -
5-phenylpentylcarbamate 

2934  20  50 

80756-85-0  S- (benzothiazol-2-yl)  (Z)-2- (2-aminotbi-(sol-4-

yl)-2-methoxyiminothioacetate 

2934 20  90 

87691-88-1  1-(I,2-bensisothiazdl-3-yl)piperazine 

hydrochloride 
2934. 30 50  111974-69-7  2-(2-[4-(dibenzo [b, f ] [l, 4) thiazepin-i:5-

yl) piperazin-1-yl] ethaxy}atha.nol 
42399-49-5  (3S, 3S) - 3 - hydroxy - 2 - (4-methoxyphenyl) •". ^ 

dihydro-l,5-benzothiazepin-4(5H)-on® 

2934  90 60  115787-67-2  2 » (2-amino-5-nltro-6-oxo-l, 6-dihydropyr : ' ixdi.n-

4-yl) -3- (3-thienyl)propionon.itrile 

117829-20-6  2~amino~7-thenyl-i,7-dihydro-4H-pyrraXoD(3~ 
d]pyrimidin-4.-one hydrochloride 

1 

CM coda 

CAS RM 

Nam* 

ANNEX n 

112887-68-0  N-{5-[(1,4-dihydro-2-mcthyl-4-oxoquinazolin-6-

ylmethyl)methylamino]-2-thenoyl}-L-glutamic 
acid 

161005-84-1  (S)-N,N-dimethyl-[3-(2-thienyl)-3-(l-

naphthyloxy)propyl]amine--phosphoric acid 
(1:1) 

104795-66-6  3-isopropoxy-5-methoxy-N-(lH-tetrazol-5-

yl)benzo[b]thiophene-2-carboxamide 

104795-67-7  3-isopropoxy-5-methoxy-N-(lH-tetrazol-5-

yl)benzo[b]thiophene-2-carboxamide--lH-
imidazole (1:1) 

104795-68-8  3-iaopropoxy-5-methoxy-N-(lH-tetrazol-5-

yl)benzo[b]thiophene-2-carboxamide. sodium 
salt 

63675-74-1  6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophene 

138564-59-7  5-methyl-2-(2-nitroanilino)thiophene-3-

2934 90 70 
2934 90 80  119221-49-7  5-[(2-aminoethyl)amino]-2-(2-

25229-97-4  2-cyano-3-morpholinoacrylamide 

carbonitrile 

diethylaminoethyl)-2H-
(l]benzothiopyrano[4,3,2-cd]indazol-8-ol 

147086-81-5  (43.6S)-5,6-dihydro-6-methyl-4H-thieno[2,3 -
b]thiopyran-4-ol 7,7-dioxide 

2934 90 98 

58-61-7  adenosine 

152305-23-2  (S)-4-(4-aminobenzyl)oxazolidin-2-one 

71420-85-4  7-amino-3-[1-(aulforaethyl)-lH-tetrazol-5-

ylthiomethyl]-3-cepham-4-carboxylic acid, 
sodium salt 

2934 90 98 

29706-84-1  3•' -azido-3 ' -deoxy-5 ' -O-tritylthymidine 
51762-51-7  benzhydryl 3-hydroxy-7-

110314-42-6  5-[(benzofuran-2-ylcarbonyl)amino]indole-2-

(phenylacetamido)cepham-4-carboxylate 

carboxylic acid 

131986-28-2  3- (4-chloro-l,2, 5-thiadiazol-3-yl)pyridine 
107452-89-1  omega-conotoxin M VIIA 
126429-09-2  2-(dichloromethyl)-4,5-dihydro-5-(4-

meaylphenyl)oxazol-4-ylmethanol 
126813-11-4  (4R,5R)-2-(dichloromethyl)-4.5-dihydro-5-(4-
mesylphenyl)oxazol-4-ylmethanol 

4097-22-7  2',3'-dideoxyadenosine 

139264-17-8  (S)-4-{[3-(2-dimethylaminoethyl)-lH-indol-5-

yl]methyl}oxazolidin-2-one 

110351-94-5  (S) -4-ethyl-4,-hydroxy-7,8-dihydro-lH-

pyrano[3,4-f]indolizine-3,6,10(4H)-trione 
140841-32-3  6- [3-fluora-5-(4-methoxytetrahydropyran-4-

94732-98-6  1-(l-{3-[2-(4-fluorophenyl)-1,3-dioxolan-2-

yl)phenoxymethyl]-l-methyl-2-quinolone 

yl]propyl}-4-piperidyl)-2,3-dihydro-lH-
benzimidazole-2-thione 

125935-03-1  (4R,6R)-G-{2- [2-(4-fluorophenyl)-5-isopropyl-

3-phenyl-4-(phenylcarbamoyl)pyrrol-1 -
yl]ethyl}-4-hydroxytetrahydro-2H-pyran-2-one 

131988,-19-7  3- (4-hexyloxy-l,2. S-thiadiazol-3-yl! -1-

methylpyridinium iodide 

147027-10-9  (1R,2S,5R)-menthyl (2R,5S)-5-(4-amino-2-oxo-

l, 2-dihydropyrimidin-l-yl)-1,3-oxathiolane-2-

CM  c o de 

CAS RM 

Mane 

ANNEX II 

147126-62-3 

104218-44-2 
27255-72-7 

0-00-0 

32231-06-4 
55612-11-8 
2935 00 90  151140-66-8 

112101-81-2 

120298-38-6 

1S0975-9S-4 
84522-34-9 

2939 10 00 
2940 00 90 
3824 90 64 

66820-84-6 
13035-61-5 
330-95-0 

104832-01-1 

0-00-0 

3824 90 64 

0-00-0 

0-00-0 

0-00-0 

3824 90 95 

3911 90 

3913 90 80 

0-00-0 

162430-94-6 

83513-48-8 

carboxylate 
(1R,2S,5R)-menthyl (2R,5R)-5-hydroxy-1,3-
oxathiolane-2-carboxylate 
3'-0-mesyl-5'-O-tritylthymidine 
3-methyl-7-(phenylacetamido)-3-cephem-4-
carboxylic acid 
(1R,2S,3S,6R)-[(S)-l-phenylethyl]-3.6-
epoxyt et rahydrophtha1imide 
1-piperonylpiperaziiMS 
5 *-O-tritylthymidine 
(4-amino-3-iodophenyl)-N-
methylmethanesulfonamide 
5-[(R)-(2-aminopropyl)]-2-
methoxybenzeneaulfonamide 
N-(5,6-dihydro-6-methyl-2-sulfamoyl-4H~ 
thieno[2,3-b]thiopyran-4-yl)acetamide 7,7-
dioxide 
5-methanesulfonamidoindole-2-carboxy1ic acid 
sodium 4-[2-(5-methylpyrazine-2-
carboxamido)ethyl]benzenesulfonamide 
(RS)-tetrahydropapaverine hydrochloride 
1,2.3,5-tetraacetyl-beta-D-ribofuranose 
1,3-bis(4-nitrophenyl)urea- -4,6-
dimathylpyrimidin-2-ol (1:1) 
(R)-6,7-dimethoxy-2-methyl-1-(3,4,5-
trimethoxybenzyl)-1,2, 3,4-
tetrahydroisoquinoline--dibenzoyl-L-tartaric 
acid (1:1) 
Intermediate concentrate obtained from a 
genetically-modified Escherichia coli 
fermentation medium, containing human 
granulocyte-macrophage colony-stimulating 
factor,- for use in the manufacture of 
medicaments of HS Mo. 3002 
Intermediate concentrate obtained from a 
genetically-modified Escherichia coli 
fermentation medium, containing human 
interferon alpha-2b; for use in the 
manufacture of medicaments of HS No. 3002 
Intermediate concentrates obtained from a 
Micromonospora inyoensis fermentation medium 
used for the manufacture of the antibiotics 
sisomiein (INN) and netilmicin (INN) 
Intermediate concentrates obtained from a 
Micromonospora purpurea fermentation medium 
used for the manufacture of the antibiotics 
gentaraicin sulfate  (ÏNNM) and isepamicin (INN) 
ethyl 7-chloro-2-oxoheptanoate, in the form of 
a solution in toluene 
1,6-hexanediamine, polymer with 1,10-
dibromodecane 
danaparoid sodium 

c2o 

Annex III 

Additions to the list of prefixes  and suffixes  which, in combination with the INNs, 
describe salts, esters or hydrates of INNs. 

51 

ACETURATE 
N-ACETYLGLYCINATE 
ACISTRATE 
ACOXIL 
AMSONATE 
BENZATHINE 
BEZOMIL 
BUCICLATE 
BUNAPSILATE 
BUTEPRATE 
BUTYL ESTER 
CARBESILATE 
p-CHLOROBENZENESULFONATE 
p-CHLOROBENZENESULPHONATE 
CICLOTATE 
CIPIONATE 
CLOSILATE 
CLOS YL ATE 
CROBEFATE 
CROMACATE 
CROMESILATE 
CYCLOPENTANEPROPIONATE 
CYCLOTATE 
CYPIONATE 
DAPROPATE 
DEANIL 
DECIL 
DIBUDINATE 
DIBUNATE 
DIETHANOLAMINE 
DIGOLIL 
N,N-DIMETHYL-beta-ALANINE 
DIOLAMINE 
DOCOSEL 
DOFOSFATE 
EDAMINE 
EDISYLATE 
EPOLAMINE 
ERBUMINE 
ETABONATE 
ETHANOLAMINE 
ETHYLENEDIAMINE 
FARNESIL 
FENDIZOATE 
FOSTEDATE 
HIBENZATE 
HYBENZATE 
HYCLATE 
o-(4-HYDROXYBENZOYL)BENZOATE 
ISOCAPROATE 
LAURIL 
LAURILSULFATE 
LAURILSULPHATE 
LAURYL 
LAURYLSULFATE 
LAURYLSULPHATE 
MEGALLATE 
METEMBONATE 
4-METHYLBICYCLO[2.2.2]OCT-2-ENE-l-CARBOXYLATE 
MOFETIL 
OCTIL 
OLAMINE 
OXOGLURATE 
PENDETIDE 

n 

PIVOXETIL 
PROXETIL 
1 -PYRROLIDINEETHANOL 
SODIUM LAURIL SULFATE 
SODIUM LAURIL SULPHATE 
SODIUM LAURYL SULFATE 
SODIUM LAURYL SULPHATE 
STEAGLATE 
TENOATE 
TEPROSILATE 
TETRADECYL HYDROGEN PHOSPHATE 
TOFESILATE 
TRICLOFENATE 
TRIETHANOLAMINE 
TRIFLUTATE 
TROLAMINE 
TROMETAMOL 
TROMETHAMINE 
TROXUNDATE 
XINAFOATE 

% 

Annex IV 

INNs which shall no longer benefit from duty free treatment 

CN code 

CAS RN 

Name 

2903 22 00 
2903 30 10 
2903 51 10 
2906 21 00 
2915 29 00 
2922 41 00 
2922 42 90 
2922 49 10 
2922 50 00 
2923 10 10 
2928 00 90 
2930 90 20 
2933 90 95 
3102 70 10 
3904 61 10 
3906 90 90 
3907 20 
3907 20 12 
3907 20 21 
3907 60 10 
3908 10 00 
3910 00 00 
3912 20 11 
3912 31 00 
3912 39 80 

79-01-6 
811-97-2 
58-89-9 
100-51-6 
82279-57-0 
56-87-1 
56-86-0 
56-40-6 
72-19-5 
67-48-1 
79-17-4 
111-48-8 
73-22-3 
156-62-7 
9002-84-0 
54182-57-9 
0-00-0 
25322-68-3 
25301-02-4 
25038-59-9 
25038-54-4 
9006-65-9 
9004-70-0 
9000-11-7 
8063-82-9 

trichloroethylene 
norflurane 
lindane 
benzyl alcohol 
zinc acetate, basic 
lysine 
glutamic acid 
glycine 
threonine 
choline chloride 
pimagedine 
thiodiglycol 
tryptophan 
calcium carbimide 
politef 
carbomer 
macrogol ester 
macrogol 
tyloxapol 
pegoterate 
policapram 
dimeticone 
pyroxylin 
carmellose 
hypromellose 

l\ 

ISSN 0254-1475 

COM(96) 563 final 

DOCUMENTS 

EN 

02  05  09  15 

Catalogue number  :  CB-C0-96-562-EN-C 

ISBN  92-78-10884-7 

Office  for Official  Publications of the European Communities 

L-2985 Luxembourg 

25